Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
42
COGT Quote, Financials, Valuation and Earnings
Last price:
$35.20
Seasonality move
:
10.36%
Day range:
$33.82 - $35.67
52-week range:
$3.72 - $43.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
55.99x
P/B ratio:
10.44x
Volume:
2M
Avg. volume:
2.4M
1-year change:
515.56%
Market cap:
$5.7B
Revenue:
--
EPS (TTM):
-$2.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
-- | -$0.54 | -- | -15.33% | $54.17 |
|
INSM
Insmed, Inc.
|
$301.5M | -$0.99 | 259.02% | -30.12% | $214.32 |
|
NUVL
Nuvalent, Inc.
|
-- | -$1.31 | -- | -10.51% | $142.39 |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$73.2M | -$0.60 | 265.04% | -39.33% | $39.00 |
|
TERN
Terns Pharmaceuticals, Inc.
|
-- | -$0.28 | -- | -8.39% | $54.25 |
|
VERA
Vera Therapeutics, Inc.
|
-- | -$1.43 | -- | -69.23% | $79.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
$35.21 | $54.17 | $5.7B | -- | $0.00 | 0% | 55.99x |
|
INSM
Insmed, Inc.
|
$162.43 | $214.32 | $34.5B | -- | $0.00 | 0% | 53.27x |
|
NUVL
Nuvalent, Inc.
|
$105.43 | $142.39 | $8.3B | -- | $0.00 | 0% | -- |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$25.15 | $39.00 | $2.3B | -- | $0.00 | 0% | 13.29x |
|
TERN
Terns Pharmaceuticals, Inc.
|
$52.72 | $54.25 | $6.1B | -- | $0.00 | 0% | -- |
|
VERA
Vera Therapeutics, Inc.
|
$40.86 | $79.00 | $2.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
27.29% | 1.085 | 4.11% | 14.08x |
|
INSM
Insmed, Inc.
|
50.57% | 1.883 | 2.03% | 3.35x |
|
NUVL
Nuvalent, Inc.
|
-- | 0.195 | -- | 15.05x |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
84.24% | -3.079 | 18.81% | 3.60x |
|
TERN
Terns Pharmaceuticals, Inc.
|
0.36% | -4.718 | 0.16% | 19.21x |
|
VERA
Vera Therapeutics, Inc.
|
11.34% | 0.014 | 2.14% | 13.37x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
-$1.2M | -$99.5M | -83.75% | -104.81% | -- | -$79.9M |
|
INSM
Insmed, Inc.
|
$217.7M | -$249.7M | -77.98% | -192.35% | -94.64% | -$294.2M |
|
NUVL
Nuvalent, Inc.
|
-- | -$102.2M | -41.59% | -41.59% | -- | -$73.3M |
|
SNDX
Syndax Pharmaceuticals, Inc.
|
$66M | -$62.5M | -55.56% | -169.76% | -91.01% | -$69.5M |
|
TERN
Terns Pharmaceuticals, Inc.
|
-$111K | -$27.7M | -28.94% | -29.05% | -- | -$19.8M |
|
VERA
Vera Therapeutics, Inc.
|
-$135K | -$94.2M | -51.22% | -57.98% | -- | -$70.1M |
Cogent Biosciences, Inc. vs. Competitors
-
Which has Higher Returns COGT or INSM?
Insmed, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -124.5%. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Insmed, Inc.'s return on equity of -192.35%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.69 $875.2M INSMInsmed, Inc.82.51% -$1.54 $1.5B -
What do Analysts Say About COGT or INSM?
Cogent Biosciences, Inc. has a consensus price target of $54.17, signalling upside risk potential of 53.84%. On the other hand Insmed, Inc. has an analysts' consensus of $214.32 which suggests that it could grow by 31.94%. Given that Cogent Biosciences, Inc. has higher upside potential than Insmed, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 INSMInsmed, Inc.17 0 0 -
Is COGT or INSM More Risky?
Cogent Biosciences, Inc. has a beta of 0.474, which suggesting that the stock is 52.579% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.100, suggesting its more volatile than the S&P 500 by 10.036%.
-
Which is a Better Dividend Stock COGT or INSM?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or INSM?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Cogent Biosciences, Inc.'s net income of -$102.5M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 53.27x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$102.5M INSMInsmed, Inc.53.27x -- $263.8M -$328.5M
-
Which has Higher Returns COGT or NUVL?
Nuvalent, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of --. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Nuvalent, Inc.'s return on equity of -41.59%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.69 $875.2M NUVLNuvalent, Inc.-- -$1.59 $1.2B -
What do Analysts Say About COGT or NUVL?
Cogent Biosciences, Inc. has a consensus price target of $54.17, signalling upside risk potential of 53.84%. On the other hand Nuvalent, Inc. has an analysts' consensus of $142.39 which suggests that it could grow by 35.06%. Given that Cogent Biosciences, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Nuvalent, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 NUVLNuvalent, Inc.15 0 0 -
Is COGT or NUVL More Risky?
Cogent Biosciences, Inc. has a beta of 0.474, which suggesting that the stock is 52.579% less volatile than S&P 500. In comparison Nuvalent, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock COGT or NUVL?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Nuvalent, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or NUVL?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Nuvalent, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$102.5M is higher than Nuvalent, Inc.'s net income of -$118.7M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Nuvalent, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus -- for Nuvalent, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$102.5M NUVLNuvalent, Inc.-- -- -- -$118.7M
-
Which has Higher Returns COGT or SNDX?
Syndax Pharmaceuticals, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -98.96%. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Syndax Pharmaceuticals, Inc.'s return on equity of -169.76%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.69 $875.2M SNDXSyndax Pharmaceuticals, Inc.96.06% -$0.78 $410.1M -
What do Analysts Say About COGT or SNDX?
Cogent Biosciences, Inc. has a consensus price target of $54.17, signalling upside risk potential of 53.84%. On the other hand Syndax Pharmaceuticals, Inc. has an analysts' consensus of $39.00 which suggests that it could grow by 55.07%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 SNDXSyndax Pharmaceuticals, Inc.10 0 0 -
Is COGT or SNDX More Risky?
Cogent Biosciences, Inc. has a beta of 0.474, which suggesting that the stock is 52.579% less volatile than S&P 500. In comparison Syndax Pharmaceuticals, Inc. has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.123%.
-
Which is a Better Dividend Stock COGT or SNDX?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Syndax Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or SNDX?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Syndax Pharmaceuticals, Inc. quarterly revenues of $68.7M. Cogent Biosciences, Inc.'s net income of -$102.5M is lower than Syndax Pharmaceuticals, Inc.'s net income of -$68M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Syndax Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 13.29x for Syndax Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$102.5M SNDXSyndax Pharmaceuticals, Inc.13.29x -- $68.7M -$68M
-
Which has Higher Returns COGT or TERN?
Terns Pharmaceuticals, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of --. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.69 $875.2M TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M -
What do Analysts Say About COGT or TERN?
Cogent Biosciences, Inc. has a consensus price target of $54.17, signalling upside risk potential of 53.84%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $54.25 which suggests that it could grow by 2.9%. Given that Cogent Biosciences, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Terns Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 TERNTerns Pharmaceuticals, Inc.3 7 0 -
Is COGT or TERN More Risky?
Cogent Biosciences, Inc. has a beta of 0.474, which suggesting that the stock is 52.579% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of -0.370, suggesting its less volatile than the S&P 500 by 136.957%.
-
Which is a Better Dividend Stock COGT or TERN?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or TERN?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Terns Pharmaceuticals, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$102.5M is lower than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$102.5M TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M
-
Which has Higher Returns COGT or VERA?
Vera Therapeutics, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of --. Cogent Biosciences, Inc.'s return on equity of -104.81% beat Vera Therapeutics, Inc.'s return on equity of -57.98%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.69 $875.2M VERAVera Therapeutics, Inc.-- -$1.39 $681.8M -
What do Analysts Say About COGT or VERA?
Cogent Biosciences, Inc. has a consensus price target of $54.17, signalling upside risk potential of 53.84%. On the other hand Vera Therapeutics, Inc. has an analysts' consensus of $79.00 which suggests that it could grow by 93.34%. Given that Vera Therapeutics, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 VERAVera Therapeutics, Inc.12 1 0 -
Is COGT or VERA More Risky?
Cogent Biosciences, Inc. has a beta of 0.474, which suggesting that the stock is 52.579% less volatile than S&P 500. In comparison Vera Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock COGT or VERA?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vera Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Vera Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or VERA?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Vera Therapeutics, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$102.5M is lower than Vera Therapeutics, Inc.'s net income of -$91.1M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Vera Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus -- for Vera Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$102.5M VERAVera Therapeutics, Inc.-- -- -- -$91.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
